Personalized Therapy Monitoring in Colorectal Cancer Patients – How maintrac® and stemtrac® can provide support
Q2 - July 1st, 2025
10am (CET, Bayreuth)
6pm (AEST, Sydney)
4pm (AWST, Perth)
9am (BST, London)
8pm (New Zealand)
and
7pm(CET, Bayreuth)
10am (PDT, Los Angeles)
1pm (EDT, New York)
6pm (BST, London)
Speaker: Prof. Dr. med. Pachmann
This is the second online forum of a four-part series in 2025.
In modern oncology, personalized therapy monitoring is becoming increasingly important,
especially for patients with metastatic colorectal cancer. Standard therapies often offer
multiple treatment options — this is where drug sensitivity testing with maintrac® provides
valuable support for clinical decision-making. Additionally, assessing the risk of metastasis with
stemtrac® allows for the early identification of high-risk patients.
In this webinar, we will present compelling clinical cases that clearly illustrate the practical
benefits of these innovative methods.
We look forward to your participation and scientific exchange.
Your team of the laboratory Pachmann GmbH & Co. KG
Your maintrac® team